GlassScriptPhysician profile
Yaser Homsi
NPI 1790943983
$7,483.71
in general payments reported to CMS, 2019-2025
64 companies · $65.85 in 2025
The $65.85 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,602 · 2020: $1,776 · 2021: $1,162 · 2022: $87.22 · 2023: $267 · 2024: $1,524 · 2025: $65.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,410 · Food and Beverage: $400 · Education: $46.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,410.00 |
| Food and Beverage | $400.21 |
| Education | $46.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $1,548.83 | 2019-2024 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $352.01 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $346.01 | 2019-2023 | Lynparza |
| Merck Sharp & Dohme LLC | $343.75 | 2019-2023 | Keytruda, Lenvima, Lynparza |
| Pfizer INC. | $280.49 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $261.86 | 2019-2020 | |
| Janssen Biotech, INC. | $261.76 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $260.19 | 2019-2023 | |
| Amgen INC. | $258.55 | 2019-2025 | |
| Incyte Corporation | $232.24 | 2019-2021 | |
| Celgene Corporation | $225.42 | 2019-2021 | |
| Exelixis INC. | $199.79 | 2019-2020 | |
| Genzyme Corporation | $188.07 | 2019-2021 | |
| Abbvie INC. | $169.90 | 2019-2024 | |
| Astellas Pharma US INC | $158.41 | 2019-2023 | Xospata |
Show all 62 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yaser Homsi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.